[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 3,552
Citations 0
This Week in JAMA
June 26, 2013

This Week in JAMA

JAMA. 2013;309(24):2515. doi:10.1001/jama.2012.174898

Aspirin use is associated with a lower risk of colorectal carcinoma—potentially through inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2). With experimental evidence of a role of RAF kinases in up-regulation of PTGS2, Nishihara and colleagues assessed whether the association of aspirin intake with colorectal carcinoma risk differs according to BRAF mutation status in an analysis of data from 2 prospective cohort studies involving 127 865 individuals. The authors found that regular aspirin use was associated with lower risk of BRAF –wild-type colorectal cancer but not BRAF -mutated cancer risk. In an editorial, Pasche discusses differential effects of aspirin before and after diagnosis of colorectal cancer.